Related Experiment Videos
Phase II study of 9-hydroxy-2N-methylellipticinium acetate
European Journal of Cancer & Clinical Oncology
|February 1, 1984
Summary
Elliptinium showed a 19% response rate in advanced breast cancer patients during a phase II trial. Further research is needed to optimize elliptinium administration for solid tumors.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Advanced solid tumors represent a significant challenge in cancer treatment.
- Novel chemotherapeutic agents are continuously investigated to improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of elliptinium in patients with advanced solid tumors.
- To determine the overall response rate and duration of response for elliptinium therapy.
Main Methods:
- A broad phase II clinical trial was conducted.
- 105 evaluable patients with advanced solid tumors received elliptinium.
- The drug was administered intravenously weekly at a dose of 100 mg/m2.
Main Results:
- An overall response rate of 19% was observed in 36 breast cancer patients, with one complete and six partial responses.
- Responses in breast cancer patients lasted 12-56 weeks.
- One partial response was noted in 21 patients with squamous cell lung cancer; no responses were seen in colon, head and neck, or other malignancies.
- Minimal myelosuppression was observed, with nausea, vomiting, xerostomia, and intravascular hemolysis being the most frequent toxicities.
Conclusions:
- Elliptinium demonstrated limited efficacy in a broad range of advanced solid tumors.
- The drug showed some activity in breast cancer and squamous cell lung cancer.
- Further investigation is required to establish optimal administration protocols for elliptinium.